How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study
about
sameAs
Is the prevalence of overactive bladder overestimated? A population-based study in FinlandBeta-3 adrenergic receptor agonist for adult with overactive bladderAnticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adultsWhich anticholinergic drug for overactive bladder symptoms in adultsAnticholinergic drugs versus other medications for overactive bladder syndrome in adultsAnticholinergic drugs versus placebo for overactive bladder syndrome in adultsAnticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adultsBotulinum toxin injections for adults with overactive bladder syndromeWhich anticholinergic drug for overactive bladder symptoms in adultsMirabegron: a review of recent data and its prospects in the management of overactive bladderThe neural control of micturitionUrodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions.Overview of the Epidemiology of Lower Urinary Tract Dysfunction in South KoreaReview of the epidemiology of overactive bladderThe efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladderClinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladderTotal urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptomsOveractive bladder syndrome and the potential role of prostaglandins and phosphodiesterases: an introductionSacral neuromodulation in overactive bladder: a review and current perspectivesEffects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic reviewTrospium chloride treatment of overactive bladderAdverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approachOveractive bladder - 18 years - Part IThe association of adiposity and overactive bladder appears to differ by gender: results from the Boston Area Community Health surveyAssessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic dataThe effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trialsBrain-bladder control network: the unsolved 21st century urological mystery.Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.Managing patients with an overactive bladder and glaucoma: a questionnaire survey of Japanese urologists on the use of anticholinergics.Prevalence, evaluation and management of overactive bladder in primary careUrinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.Analysis of the prevalence and associated factors of overactive bladder in adult Korean men.Drug treatment of urological symptoms: estimating the magnitude of unmet need in a community-based sampleHealth economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in SpainAssociation of Preexisting Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients.Epidemiology of lower urinary tract symptoms: emphasis on the status in Korea.CUA guideline on adult overactive bladderCorrelation between overactive bladder symptom score and neuropsychological parameters in Alzheimer's disease patients with lower urinary tract symptom.Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.Urinary retention in female OAB after intravesical Botox injection: who is really at risk?
P2860
Q21144463-2B753DC9-3FB2-4D57-9061-ADC200A983D6Q24187596-074DD2D1-2AD0-4B7D-8F28-F9E0CA9FFDD5Q24202075-8F99C848-6E2A-485C-A5BA-5D8E3FBA6C54Q24203880-1BBCDDB2-FC79-47C9-B36A-B7FED1350548Q24243527-252BD3E1-D411-497D-89EF-E9BF0112CFCAQ24243870-67E83E56-8D32-41B0-A40A-FEADF3858E41Q24243956-C266891D-A656-460E-805A-F94D90B14FCFQ24243963-16F24AA6-404A-431B-94CC-7C996D56B664Q24246651-EE782A5B-59F0-4A1B-8804-0D9872CE483AQ24617239-9D0C830A-569F-4BF2-89E8-228AC041EC95Q24619130-D97B93AA-ECC2-414C-8762-70ABC7B00B3BQ24812265-C0C514B1-42FD-4365-8585-C71393E5D223Q26744685-BF6943CE-D2B5-4BC1-906E-ED8A99881CEDQ26746439-3188D8F0-F081-408C-9ABA-33C4950E5F52Q26770419-52297C71-16CF-47C4-A61C-A32CAD72103FQ26824182-303C277A-5D12-4C27-B15C-86EFC5979A00Q27001248-BF46AC2A-DA52-4B88-A14C-A9FE78C2862AQ27011502-F9CC5CE3-8C57-4C2E-97C6-EB7F61A97A42Q28066372-650376D7-5772-4405-96D8-42CBE16E2B7EQ28273396-E00214DB-FBEF-430F-8AE0-98D282B10FFCQ28308162-387344EC-D27C-4CE5-BF5C-94A659220104Q28742444-7F9F2C7A-3FF8-462D-885E-A3AA91BE1404Q30388069-E3A22940-1767-47B3-8968-48727FCC0F27Q30428136-0515EBD6-CF19-4DAB-930E-C4EED114F86BQ30891304-38F16B96-9A81-4686-81D7-D3C74B80F84DQ30894093-7B026EA6-F6B9-4143-8BA5-B2555C07AF5EQ30895519-7323BFFC-980B-47C6-BFDA-6F1176E64187Q31013378-6906096D-D01E-4307-8C28-43E3D0FBF23CQ33210669-4AB3663D-EACF-4321-A898-54C14E5EF8B0Q33402658-191C49B1-0314-4489-8E73-0AE82B191073Q33515909-62A1CD5A-37BE-4CD3-9A53-B4E9008F83EFQ33563105-9BA1772D-88B1-44B9-BC98-7E6F4F08C7BBQ33578216-D8E9E771-AD8D-4F32-B7CE-AC78DB7DD570Q33588346-0201411E-A604-4FC3-96F0-2FBB768F9C13Q33616692-ECB3C31C-84DB-420E-B242-0460D5F05936Q33633711-F134DD81-4F0A-41F4-AE0F-FB875DBC2310Q33665026-641BB442-483F-48BB-9915-1EEA2F8839A5Q33692634-CD4FB056-27D5-477C-BF14-490B60D76948Q33696642-E17F129C-DF2D-487E-A2C2-E2704EEEE6E0Q33705306-40C78D25-0542-4DEE-8C1D-F6F0859069C7
P2860
How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
How widespread are the symptom ...... ulation-based prevalence study
@ast
How widespread are the symptom ...... ulation-based prevalence study
@en
How widespread are the symptom ...... ulation-based prevalence study
@nl
type
label
How widespread are the symptom ...... ulation-based prevalence study
@ast
How widespread are the symptom ...... ulation-based prevalence study
@en
How widespread are the symptom ...... ulation-based prevalence study
@nl
prefLabel
How widespread are the symptom ...... ulation-based prevalence study
@ast
How widespread are the symptom ...... ulation-based prevalence study
@en
How widespread are the symptom ...... ulation-based prevalence study
@nl
P2093
P2860
P3181
P1433
P1476
How widespread are the symptom ...... ulation-based prevalence study
@en
P2093
P2860
P3181
P356
10.1046/J.1464-410X.2001.02228.X
P407
P577
2001-06-01T00:00:00Z